Overview
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-09-01
2025-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants<3rd percentile* born at 26-32 weeks GA.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Elgan Pharma Ltd.
Criteria
Inclusion Criteria:- Male or female preterm infant born less than 26 weeks GA or Intra-Uterine Growth
Restricted infants born between 26+0 to 31+6 GA.
- Birth weight ≥ 450g
- Singleton or twin birth
Exclusion Criteria:
N/A